NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
Rhea-AI Summary
Nutex Health (NASDAQ: NUTX) reported full-year 2025 results with total revenue of $875.3M, up 82.4% versus 2024, and net income attributable of $70.8M. Hospital division revenue was $844.2M, driven partly by IDR arbitration outcomes. The Board authorized a $25.0M share repurchase program over six months.
Full-year Adjusted EBITDA was $259.6M, cash from operations was $248.1M, cash and equivalents ended at $185.6M, and stock-based compensation rose to $117.0M.
Positive
- Total revenue +82.4% to $875.3M (2025 vs 2024)
- Hospital division revenue +88.0% to $844.2M
- Adjusted EBITDA +152.6% to $259.6M
- Net cash from operations of $248.1M for 2025
- Cash and cash equivalents of $185.6M at year-end
- Board authorized $25.0M share repurchase program
Negative
- Q4 2025 revenue -41.1% to $151.7M versus Q4 2024
- One-time $55.0M arbitration true-up reduced Q4 revenue
- Q4 Adjusted EBITDA decreased 80.8% to $16.6M
- Stock-based compensation surged to $117.0M in 2025
Key Figures
Market Reality Check
Peers on Argus
NUTX is down 2.86% while momentum peers like CMPS (+6.86%) and CYH (+2.05%) are up, and several fundamental peers show mixed, generally smaller moves. This points to a stock-specific reaction to Nutex’s earnings and new buyback.
Previous Buybacks,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Aug 14 | Earnings & buyback | Positive | -16.4% | Preliminary Q2 2025 results plus new $25M stock repurchase authorization. |
The only prior combined buyback/earnings announcement with this tag saw a sharply negative reaction despite strong growth metrics and a repurchase program, suggesting a tendency for the stock to sell off around such news.
Over the past several months, Nutex has highlighted rapid growth driven by its hospital division and use of arbitration under the No Surprises Act. A prior Aug 14, 2025 update paired strong preliminary Q2 2025 results with a $25 million repurchase program, yet the stock fell 16.4%. Today’s full-year 2025 report and second repurchase authorization build directly on that strategy of combining robust financial performance with capital returns.
Historical Comparison
Past combined buyback/earnings news triggered an average move of -16.4%. Today’s -2.86% reaction is milder than that prior drawdown.
Nutex previously paired preliminary Q2 2025 results with a $25M repurchase plan. The current release advances this theme with full-year 2025 results and authorization of a second stock repurchase program.
Market Pulse Summary
This announcement combines strong 2025 financial performance with a second $25.0M stock repurchase program. Revenue grew to $875.3M, Adjusted EBITDA reached $259.6M, and operating cash flow was $248.1M, supported by arbitration-related revenue of $527.8M. At the same time, Q4 revenue declined to $151.7M and the business remains exposed to regulatory and arbitration dynamics. Investors may watch future quarters for trends in hospital visits, arbitration outcomes, and cash generation.
Key Terms
ebitda financial
adjusted ebitda financial
independent dispute resolution ("idr") regulatory
stock repurchase program financial
rule 10b-18 regulatory
rule 10b5-1 regulatory
form 10-k regulatory
AI-generated analysis. Not financial advice.
FULL YEAR 2025 HIGHLIGHTS:
- Total revenue of
$875.3 million $479.9 million 82.4% - Net income attributable to Nutex Health of
$70.8 million $52.1 million $18.7 million - Diluted EPS of
$10.48 $9.69 - EBITDA of
$168.6 million $98.8 million 70.6% - Adjusted EBITDA of
$259.6 million $102.8 million 152.6% - Net cash from operating activities of
$248.1 million
Financial highlights for the twelve months ended December 31, 2025:
- Total revenue increased
$395.3 million $875.3 million $479.9 million 82.4% . The hospital division drove most of this growth, generating$844.2 million 188.0% from$449.1 million 73.4% in 2025 compared to 2024. - Of the 844.2 million in hospital revenue,
$527.8 million 63% ) related to a combination of both higher acuity claims as well as success through the Independent Dispute Resolution ("IDR") process. - Regarding arbitration-related revenue: we have submitted between 50
-60% of our claims through the IDR process. When an award determination is made, we currently prevail in over85% of those determinations, and have an average collection rate of over85% of the determination wins. - Arbitration costs approximate
26% of the arbitration related revenue. - Total stock-based compensation expense for the twelve months ended December 31, 2025 was
$117.0 million $16.6 million - Operating income for the twelve months ended December 31, 2025 was
$275.6 million $130.7 million $144.9 million - Net income attributable to Nutex Health for the twelve months ended December 31, 2025 of
$70.8 million $52.1 million $70.8 million $117.0 million $52.1 million $16.6 million - Diluted EPS of
$10.48 $9.69 - EBITDA attributable to Nutex Health of
$168.6 million $98.8 million 70.6% . - Adjusted EBITDA attributable to Nutex Health of
$259.6 million $102.8 million 152.6% . - Total visits at the Hospital Division were 188,279 for the twelve months ended December 31, 2025, as compared to 168,388 for the same period in 2024, an increase of 19,891 or
11.8% . Visits at mature hospitals increased by1.3% in the twelve months ended December 31, 2025 as compared to the same period in 2024. - Net cash from operating activities of
$248.1 million - As of December 31, 2025, the Company had total assets of
$918.5 million $185.6 million $29.2 million
Financial highlights for the three months ended December 31, 2025:
- Total revenue decreased
$105.9 million $151.7 million $257.6 million 41.1% .- The Company attributes the
$105.9 million
- The Company attributes the
1. A one‑time
- The one-time cumulative arbitration true-up resulted from a mid‑2025 CMS directive instructing the certified independent dispute resolution entities to address and clear their backlog of disputes. The associated catch‑up reduced the number of active disputes compared to the same period in 2024 and contributed to lower net revenue for the quarter.
2. Arbitration revenues of
- After considering the impact of the adjustments above, the 2025 fourth quarter revenue would be
$206.7 million $188.6 million $18.1 million
- After considering the impact of the adjustments above, the 2025 fourth quarter revenue would be
- Total stock-based compensation expense for the three months ended December 31, 2025 was
$(2.6) million $14.6 million - Operating income for the three months ended December 31, 2025 was
$30.9 million $114.3 million $83.4 million - Net income attributable to Nutex Health for the three months ended December 31, 2025 of
$11.8 million $61.6 million $11.8 million $(2.6) million $61.6 million $14.6 million - EBITDA attributable to Nutex Health of
$25.7 million $78.9 million 67.4% . - Adjusted EBITDA attributable to Nutex Health of
$16.6 million $86.7 million 80.8% . - Total visits at the Hospital Division were 48,205 for the three months ended December 31, 2025, as compared to 45,444 for the same period in 2024, an increase of 2,761 or
6.1% . Visits at mature hospitals decreased by0.3% in the three months ended December 31, 2025 as compared to the same period in 2024. - Net cash from operating activities of
$70.4 million $0.1 million
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
"We are continuing to add to a record year with
"We are thrilled to share our exceptionally strong 2025 financial results with our investors. Compared to 2024, we delivered improvements across nearly all key financial metrics. During 2025 and early 2026, we successfully opened three new micro-hospitals, further expanding our national footprint. In addition, both ER visits and inpatient admissions grew year over year, reflecting increased demand and strengthened operational performance," stated Tom Vo, M.D, MBA, Chairman and Chief Executive Officer of Nutex Health.
Dr. Vo added: "Importantly, we also remediated all previously disclosed material weaknesses in internal controls over financial reporting in 2025—an accomplishment that enhances transparency, highlights the strength in our internal controls, and reinforces investor confidence. Looking ahead, we are well positioned for continued growth through a balanced strategy that includes both de novo hospital development and increased patient volumes across our existing facilities."
For more details on the Company's financial results for the twelve months ended December 31, 2025, please refer to our Annual Report on Form 10-K filed with the
Share Repurchase Program
The Board of Directors has authorized a second stock repurchase program of up to
The timing of any repurchases and the number of shares repurchased are subject to the discretion of the Company and may be affected by various factors, including general market and economic conditions, the market price of the Company's common stock, the Company's earnings, financial condition, capital requirements and levels of indebtedness, legal requirements, and other factors that management may deem relevant. The share repurchase program authorization does not obligate the Company to acquire any shares of its common stock and may be amended, suspended or discontinued at any time.
Conference Call on Fourth Quarter and Full Year 2025 Results
The Company will host a conference call on Friday, March 6, 2026 at 9:30 a.m. CT to discuss its results for the fourth quarter and full year of 2025.
Participant Listening: 1-877-407-9208 or 1-201-493-6784
Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=company&r=true&B=6
To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website.
NUTEX HEALTH INC. | ||||
CONSOLIDATED BALANCE SHEETS | ||||
December 31 | ||||
(In thousands, except share and per share amounts) | 2025 | 2024 | ||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 185,574 | $ 40,640 | ||
Restricted cash | 297 | — | ||
Restricted short-term investments | — | 2,941 | ||
Accounts receivable | 319,440 | 232,449 | ||
Accounts receivable - related parties | 5,978 | 3,602 | ||
Inventories | 2,866 | 2,850 | ||
Prepaid expenses and other current assets | 24,656 | 9,997 | ||
Total current assets | 538,811 | 292,479 | ||
Property and equipment, net | 94,581 | 77,933 | ||
Operating lease right-of-use assets | 26,955 | 27,872 | ||
Financing lease right-of-use assets | 222,367 | 218,889 | ||
Intangible assets, net | 21,230 | 15,530 | ||
Goodwill, net | 13,919 | 13,919 | ||
Deferred tax assets | — | 7,987 | ||
Other assets | 662 | 711 | ||
Total assets | $ 918,525 | $ 655,320 | ||
Liabilities and Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 45,863 | $ 9,614 | ||
Accounts payable - related parties | 3,104 | 806 | ||
Lines of credit | 740 | 3,554 | ||
Current portion of long-term debt | 13,336 | 14,395 | ||
Operating lease liabilities, current portion | 2,152 | 2,080 | ||
Financing lease liabilities, current portion | 7,077 | 7,705 | ||
Accrued arbitration expenses | 49,743 | 47,742 | ||
Accrued income tax expense | 867 | 26,533 | ||
Accrued stock-based compensation | 8,256 | 16,356 | ||
Accrued expenses and other current liabilities | 26,773 | 25,440 | ||
Total current liabilities | 157,911 | 154,225 | ||
Long-term debt, net | 29,174 | 22,466 | ||
Non-current operating lease liabilities, net | 30,037 | 30,617 | ||
Non-current financing lease liabilities, net | 268,877 | 259,479 | ||
Deferred tax liabilities | 9,089 | — | ||
Total liabilities | 495,088 | 466,787 | ||
Commitments and contingencies (Note 10) | ||||
Equity: | ||||
Common stock, | 7 | 6 | ||
Additional paid-in capital | 615,627 | 489,409 | ||
Accumulated deficit | (286,187) | (356,976) | ||
Nutex Health Inc. equity | 329,447 | 132,439 | ||
Noncontrolling interests | 93,990 | 56,094 | ||
Total equity | 423,437 | 188,533 | ||
Total liabilities and equity | $ 918,525 | $ 655,320 | ||
See accompanying notes to the consolidated financial statements. | ||||
NUTEX HEALTH INC. | ||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||
Year ended December 31, | ||||||
(In thousands, except per share amounts) | 2025 | 2024 | 2023 | |||
Revenue: | ||||||
Hospital division | $ 844,162 | $ 449,064 | $ 218,070 | |||
Population health management division | 31,095 | 30,885 | 29,576 | |||
Total revenue | 875,257 | 479,949 | 247,646 | |||
Operating costs and expenses: | ||||||
Payroll | 158,081 | 117,527 | 108,378 | |||
Contract services | 190,315 | 100,757 | 42,350 | |||
Medical supplies | 17,241 | 15,285 | 14,151 | |||
Depreciation and amortization | 20,530 | 18,972 | 17,592 | |||
Other | 44,809 | 31,146 | 30,401 | |||
Total operating costs and expenses | 430,976 | 283,687 | 212,872 | |||
Gross profit | 444,281 | 196,261 | 34,774 | |||
Corporate and other costs: | ||||||
Facilities closing costs | — | — | 217 | |||
Acquisition costs | — | — | 44 | |||
Stock-based compensation | 117,003 | 16,555 | 2,836 | |||
Impairment of assets | — | 3,887 | 29,082 | |||
Impairment of goodwill | — | 3,197 | 1,139 | |||
General and administrative expenses | 51,653 | 41,924 | 33,230 | |||
Total corporate and other costs | 168,656 | 65,563 | 66,548 | |||
Operating income (loss) | 275,625 | 130,698 | (31,774) | |||
Interest expense, net | 22,226 | 19,932 | 16,318 | |||
Loss on warrant liability | — | 1,609 | — | |||
Other (income) expense | 8,618 | (669) | 399 | |||
Income (loss) before taxes | 244,781 | 109,826 | (48,491) | |||
Income tax expense (benefit) | 64,424 | 15,020 | (5,067) | |||
Net income (loss) | 180,357 | 94,806 | (43,424) | |||
Less: net income attributable to noncontrolling interests | 109,568 | 42,709 | 2,363 | |||
Net income (loss) attributable to Nutex Health Inc. | $ 70,789 | $ 52,097 | $ (45,787) | |||
Earnings (loss) per common share | ||||||
Basic | $ 11.13 | $ 10.23 | $ (10.39) | |||
Diluted | $ 10.48 | $ 9.69 | $ (10.39) | |||
See accompanying notes to the consolidated financial statements. | ||||||
NUTEX HEALTH INC. | ||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
Year Ended December 31, | ||||||
(In thousands) | 2025 | 2024 | 2023 | |||
Cash flows from operating activities: | ||||||
Net income (loss) | $ 180,357 | $ 94,806 | $ (43,424) | |||
Adjustment to reconcile net income (loss) to net cash from operating | ||||||
Depreciation and amortization | 20,530 | 18,972 | 17,592 | |||
Impairment of assets | — | 3,887 | 29,082 | |||
Impairment of goodwill | — | 3,197 | 1,139 | |||
Derecognition of goodwill | — | 453 | — | |||
Loss on warrant liability | — | 1,609 | — | |||
Stock-based compensation expense | 117,003 | 16,555 | 2,836 | |||
Changes to deferred taxes | 17,076 | (13,133) | (5,707) | |||
Debt accretion expense | 902 | 1,042 | 1,210 | |||
Loss on lease termination | — | — | 58 | |||
Changes in operating assets and liabilities: | ||||||
(Increase)/Decrease in Accounts receivable | (86,943) | (173,957) | (970) | |||
(Increase)/Decrease in Accounts receivable - related party | (2,376) | 550 | (3,614) | |||
(Increase)/Decrease in Inventories | (16) | 540 | 143 | |||
(Increase)/Decrease in Prepaid expenses and other current assets | (14,610) | (7,021) | (817) | |||
(Increase)/Decrease in Operating right-of-use assets | 917 | 1,147 | 1,632 | |||
Increase/(Decrease) in Accounts payable | 35,555 | (8,682) | (4,715) | |||
Increase/(Decrease) in Accounts payable - related party | 2,298 | (2,037) | 2,467 | |||
Increase/(Decrease) in Operating lease liabilities | (508) | (1,528) | (1,501) | |||
Increase/(Decrease) in Accrued arbitration expenses | 2,002 | 47,742 | — | |||
Increase/(Decrease) in Accrued income tax expense | (25,666) | 26,533 | — | |||
Increase/(Decrease) in Accrued expenses and other current liabilities | 1,604 | 12,478 | 5,846 | |||
Net cash provided by operating activities | 248,125 | 23,153 | 1,257 | |||
Cash flows from investing activities: | ||||||
Acquisitions of property and equipment | (2,526) | (2,304) | (9,497) | |||
Purchase of restricted short-term investment | — | (2,941) | — | |||
Cash related to sale of business | — | (361) | — | |||
Proceeds from restricted short-term investment | 1,596 | — | — | |||
Payments for acquisitions of businesses, net of cash acquired | — | — | (704) | |||
Cash related to asset acquisition | (4,312) | — | — | |||
Cash related to deconsolidation of Real Estate Entities | — | — | (1,039) | |||
Net cash used in investing activities | (5,242) | (5,606) | (11,240) | |||
Cash flows from financing activities: | ||||||
Proceeds from lines of credit | 5,043 | 2,262 | 2,341 | |||
Proceeds from notes payable | — | 7,015 | 16,953 | |||
Proceeds from convertible notes | — | — | 4,910 | |||
Repayments of lines of credit | (7,857) | (2,079) | (1,593) | |||
Repayments of notes payable | (11,382) | (9,969) | (16,479) | |||
Repayments of finance leases | (5,244) | (4,628) | (3,485) | |||
Proceeds from common stock issuance, net issuance costs | — | 9,202 | — | |||
Proceeds from exercise of warrants | — | 2,373 | — | |||
Cash related to stock repurchases and retirements | (5,000) | — | — | |||
Members' contributions | 767 | 3,353 | 298 | |||
Members' distributions | (74,276) | (6,438) | (5,215) | |||
Net cash provided by (used in) financing activities | (97,949) | 1,091 | (2,270) | |||
Net change in cash and cash equivalents | 144,934 | 18,638 | (12,253) | |||
Cash and cash equivalents - beginning of the period | 40,640 | 22,002 | 34,255 | |||
Restricted cash - beginning of period | — | — | — | |||
Cash and cash equivalents and restricted cash - beginning of period | 40,640 | 22,002 | 34,255 | |||
Cash and cash equivalents - end of period | 185,574 | 40,640 | 22,002 | |||
Restricted cash - end of period | 297 | — | — | |||
Cash and cash equivalents and restricted cash - end of period | $ 185,871 | $ 40,640 | $ 22,002 | |||
See accompanying notes to the consolidated financial statements. | ||||||
Non-GAAP Financial Measures (Unaudited)
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net loss to Adjusted EBITDA is included below.
Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance.
Adjusted EBITDA is not intended to serve as an alternative to
Year Ended December 31, | |||||
2025 | 2024 | 2023 | |||
Reconciliation of net income (loss) attributable to Nutex Health Inc. to | |||||
Net income (loss) attributable to Nutex Health Inc. | $ 70,789 | $ 52,097 | $ (45,786) | ||
Depreciation and amortization | 20,530 | 18,972 | 17,592 | ||
Interest expense, net | 22,226 | 19,932 | 16,318 | ||
Income tax expense (benefit) | 64,424 | 15,020 | (5,067) | ||
Allocation to noncontrolling interests | (9,385) | (7,176) | (5,546) | ||
EBITDA | 168,584 | 98,845 | (22,489) | ||
Facility closing costs | — | — | 217 | ||
Acquisition costs | — | — | 43 | ||
Loss on warrant liability | — | 1,609 | — | ||
Stock-based compensation | 117,003 | 16,555 | 2,836 | ||
Impairment of assets | — | 3,887 | 29,082 | ||
Impairments of goodwill | — | 3,197 | 1,139 | ||
Finance lease payments(1) | (26,022) | (21,319) | (16,658) | ||
Adjusted EBITDA | $ 259,565 | $ 102,774 | $ (5,830) | ||
Three months ended | Three months ended | ||
Unaudited | Unaudited | ||
Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted | |||
Net income (loss) attributable to Nutex Health Inc. | $ 11,834 | $ 61,612 | |
Depreciation and amortization | 5,187 | 5,280 | |
Interest expense, net | 4,976 | 5,052 | |
Income tax expense | 9,286 | 9,152 | |
Allocation to noncontrolling interests | (5,570) | (2,195) | |
EBITDA | 25,713 | 78,901 | |
Loss on warrant liability | — | 536 | |
Stock-based compensation | (2,603) | 14,603 | |
Impairment of assets | — | (11) | |
Finance lease payments(1) | (6,510) | (7,363) | |
Adjusted EBITDA | $ 16,600 | $ 86,666 |
(1) | Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business. |
About Nutex Health Inc.
Headquartered in
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 27 facilities in 12 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations. Through our Management Services Organization, we provide management, administrative and other support services to our affiliated hospitals and physician groups.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result" "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, regulatory and litigation uncertainty under the No Surprises Act, lawsuits filed by health insurance providers against our third party provider in the arbitration process, sales of a substantial amount of our Common Stock by our stockholders, our obligation to issue additional shares of our common stock to former doctor owners of under construction hospitals, manipulative short seller reports, the impact of litigation and disputes, our ability to successfully execute our growth strategy, economic conditions, dependence on management, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2025 under the heading "Risk Factors" in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-2025-financial-results-and-announces-second-stock-repurchase-program-302706111.html
SOURCE Nutex Health, Inc.
FAQ
What were Nutex Health (NUTX) full-year 2025 revenue and net income figures?
Why did Nutex Health (NUTX) Q4 2025 revenue fall compared to Q4 2024?
What is the scope and purpose of Nutex Health's (NUTX) new $25.0M buyback program?
How did arbitration/IDR outcomes affect Nutex Health's (NUTX) 2025 hospital revenue?
What were Nutex Health's (NUTX) cash and liquidity positions at year-end 2025?
